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PIEWPOINT
he Dying Stem Cell Hypothesis
mmune Modulation as a Novel Mechanism
or Progenitor Cell Therapy in Cardiac Muscle
homas Thum, MD,*† Johann Bauersachs, MD,† Philip A. Poole-Wilson, MD, FRCP,*
ans-Dieter Volk, MD, PHD,‡ Stefan D. Anker, MD, PHD*§
ondon, United Kingdom; and Würzburg and Berlin, Germany
Stem cell transplantation after myocardial infarction has been claimed to restore cardiac
function, but the underlying mechanism remains unclear. A minority of transplanted cells
become adherent in heart tissue and contribute to neovascularization, whereas many donor
cells die from apoptosis. We propose that apoptosis of transplanted cells modulates local
tissue reactions. Apoptotic cells impact on immune reactivity by down-regulating innate and
adaptive immunity, deactivating macrophages and dendritic cells, and stimulating regulatory
T cells. This leads to reduced scar formation, repressed myocardial apoptosis, and improved
cardiac outcome. (J Am Coll Cardiol 2005;46:1799–802) © 2005 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.07.053of Cardiology Foundation
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scute myocardial infarction (AMI) often leads to conges-
ive heart failure and is one of the most frequent causes of
ospital stays in developed countries (1). Despite pharma-
ological treatment and mechanical revascularization tech-
iques, there is no effective therapy to replace infarcted
yocardium. Transplantation of autologous stem cells iso-
ated from peripheral blood or bone marrow into the site of
ardiac ischemia has been claimed to improve cardiac
unction (reviewed in von Harsdorf et al. [2]). It is not
nown whether such benefit is mediated by the transplanted
ells themselves, recruitment of resident cardiac stem cells
3), or by activation of, as yet, unidentified paracrine or
mmunologic mechanisms. The low number of transplanted
ells detectable in heart tissue makes a direct mechanism
nlikely.
Acute immune activation plays a role in most acute
linical manifestations of coronary atherosclerosis, and AMI
s associated with local and systemic inflammation (4,5).
fter AMI, inflammatory cytokines contribute to myocar-
ial apoptosis, necrosis, and scar formation, leading to the
evelopment of heart failure (6). In humans, apoptosis after
yocardial infarction occurs mainly in the border zones or
ven in the remote areas of ischemia (7,8); however, necrosis
s the predominant mode of cell death in the infarcted
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ccepted July 12, 2005.yocardium and might be primarily responsible for trigger-
ng the inflammatory response (9).
In previous clinical trials, in the context of AMI, stem
ells from peripheral blood or whole bone marrow were
solated from patients and were either injected into the
oronary vessel of the infarct area (2,10,11) or directly into
he ischemic heart muscle (2,12). The viability of cells
efore injection was in the range of 75% to 95% (2,10–12),
hich means that a proportion of injected cells were already
poptotic or necrotic at the time of injection (or transplan-
ation). A further proportion of healthy injected living cells
ikely become apoptotic within heart tissue because of
xposure to various proapoptotic or cytotoxic factors in an
schemic environment (13).
Apoptotic cells are able to regulate local immune reac-
ions, and the effect is amplified after AMI (4,14). The
ffects of exogenous transplanted apoptotic cells into areas
f AMI on immunity, neovascularization, and cardiac out-
ome are unknown.
HE DYING STEM CELL HYPOTHESIS
e propose that improved cardiac function after application
f stem cells to patients with AMI can be explained by the
odulation of local immune reactions in response to apop-
osis of transplanted cells (Fig. 1).
Delivery of “danger” signals via Toll-like receptor (TLR)
ctivation plays a key role in activating both innate (activa-
ion of phagocytes) and adaptive (activation of antigen-
resenting cells, particularly dendritic cells) immunity (15).
t is well established that microbial products, like endotoxin,
acterial CpG-rich deoxyribonucleic acid, viral ribonucleic
cid, among others, trigger a broad set of TLRs. Endoge-
ous ligands (e.g., heat-shock proteins) are released by
tressed and necrotic cells after ischemia/reperfusion injury
nd stimulate, particularly, TLR-4, resulting in local in-
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The Dying Stem Cell Hypothesis November 15, 2005:1799–802ammation. In addition, tissue-resident immature antigen-
resenting cells are triggered, via TLR-4, to mature and
igrate to secondary lymphoid organs, where they stimulate
he clonal expansion and differentiation of effector T cells
16). Homing of activated T cells into the injured tissue
urther amplifies local inflammation (Fig. 1A). In contrast
o stressed and necrotic cells, apoptotic cells inhibit inflam-
ation, as detailed in Figure 1B (17,18). Recognition of
poptotic cells by professional phagocytes (macrophages and
endritic cells) requires exposure of phosphatidylserine
PS), a phospholipid normally limited to the inner leaflet of
he plasma membrane bilayer, on the surface of the apopto-
ic cell and ligation by the PS receptor of the phagocyte
Fig. 1). Apoptotic cell ingestion by macrophages induces
xpression of the anti-inflammatory cytokines, such as
nterleukin (IL)-10 and transforming growth factor (TGF)-
eta. The increased expression of anti-inflammatory cyto-
ines by macrophages phagocytosing apoptotic cells might
uppress synthesis of pro-inflammatory mediators (e.g.,
umor necrosis factor [TNF]-alpha, IL-1-beta, and IL-6) in
he infarcted heart, resulting in accelerated resolution of the
nflammatory response. Apoptotic cells are also recognized
y immature dendritic cells, which are present in all tissues,
ncluding heart (16,19). This might additionally lead to
nhanced tissue-specific production of anti-inflammatory
ytokines and down-regulation of inflammatory mediators,
s detailed in Figure 1.
A variety of inflammatory cytokines, including IL-6,
nhance scar formation after AMI (6). Apoptotic trans-
lanted cells could change, at least in part, the immune
tatus of the infarcted myocardium from inflammation to an
nti-inflammatory state (20). Recruited inflammatory cells
lso undergo apoptotic cell death, and their phagocytic
limination might play a role in resolution of inflammation
y promoting secretion of anti-inflammatory cytokines such
s TGF-beta or IL-10 (21). Apoptosis occurs mainly at the
order zones of ischemia after myocardial infarction (7,8);
njection of cells directly to the site of ischemia would
ignificantly increase the amount of cells that, in turn, could
ecome apoptotic. Such modulation of the local inflamma-
ory response might suppress inflammatory injury, prevent
xpansion of the inflammatory infiltrate, and might, in part,
xplain the beneficial effects of cell transplantation in
atients with AMI. In contrast, transplantation of a signif-
cant amount of necrotic cells would lead to an acceleration
f inflammation in the infarcted heart. This problem could
urther be exaggerated when dead or necrotic cells enter or
Abbreviations and Acronyms
AMI  acute myocardial infarction
IL  interleukin
PS  phosphatidylserine
TGF  transforming growth factor
TLR  Toll-like receptorre transplanted to adjacent normal myocardium. This must ae avoided in future clinical trials, and testing cells for
ecrosis should be a prerequisite before transplantation.
UPPORT OF THE HYPOTHESIS
utologous blood exposed ex vivo to oxidative stress to
nduce cell apoptosis and administered intramuscularly de-
reases the production of inflammatory mediators, increases
nti-inflammatory cytokines, and decreases cellular injury
22–24). Immune modulation therapy has been shown to be
afe and led to significantly improved vascular endothelial
unction in the first human trials in peripheral arterial
isease (23). In a pilot study in patients with advanced
hronic heart failure, immune modulation therapy signifi-
antly reduced risk of death and hospitalization (25). Pre-
reatment of spontaneously hypertensive rats with apoptotic
ells reduced severe renal ischemia reperfusion injury (26).
irect instillation of apoptotic cells enhanced the resolution
f acute inflammation in the lung (27). In this study,
poptotic cells with externally exposed PS induced TGF-
eta1 secretion, resulting in an accelerated resolution of
nflammation. This in vivo study nicely demonstrates the
roposed concept of anti-inflammatory actions of apoptotic
ells.
MPLICATIONS OF THE HYPOTHESIS
f our hypothesis was true, the cell type of stem cells
ransplanted to the infarcted myocardium would play only a
inor role for improved cardiac function. The local immune
esponses to implanted cells might be of greater importance.
nti-inflammatory and cytoprotective signaling mecha-
isms, in response to transplanted apoptotic cells or cells
ecoming apoptotic soon after transplantation, might ex-
lain the advantageous cardiac outcome after stem cell or
one marrow transplantation after AMI. Transplantation to
reas of infarction of any cells (e.g., blood leukocytes)
riggered ex vivo to undergo apoptosis could lead to a better
ardiac outcome.
If the beneficial effects of progenitor cell therapy are due
o PS-mediated deactivation of macrophages and dendritic
ells, drugs that engage the PS receptors might accelerate
esolution of inflammation, decreasing injury in the in-
arcted myocardium. That would negate the need to trans-
lant cells at all.
The hypothesis might be applicable to any cell transplan-
ation therapy that applies cells to immunologically active
issue.
ESTING THE HYPOTHESIS
e suggest transplanting apoptotic progenitor cells after
odification by ex vivo exposure to specific physicochemical
tressors, including oxygen, ultraviolet light, and elevated
emperature into areas of ischemia in an animal model of
MI. For comparison, healthy endothelial progenitor cellsnd ex vivo stressed autologous whole blood should be used
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November 15, 2005:1799–802 The Dying Stem Cell Hypothesisigure 1. (A) Immune pathophysiology of myocardial injury. Ischemic injury damages parenchymal cells, resulting in exposition of heat-shock proteins
HSPs) that trigger tissue-resident macrophages and immature dendritic cells (DCs) via Toll-like receptor 4 (TLR-4) activation. Activated macrophages
elease several inflammatory cytokines, further amplifying tissue injury, whereas immature DCs undergo maturation and migration to secondary lymphoid
issues. After DC–T-cell interaction, HSP-specific T cells undergo clonal expansion and effector–T-cell differentiation. Homing of these cells to the injured
issue further amplifies local inflammation. (B) Apoptotic cells interact with the immune pathophysiology of myocardial injury. Transplanted, ex vivo,
nduced apoptotic cells or cells undergoing in vivo massive apoptosis inhibit macrophages and DCs via interaction of their surface phosphatidylserine with
he respective receptors (PS-R) on the immune cells. As a result, local release of anti-inflammatory cytokines like transforming growth factor (TGF)-beta
nd interleukin (IL)-10 rises (14,20), maturation and migration of DCs and T helper type 1 (Th1) activation is inhibited (16,17), and activation of
egulatory T cells (T ) is enhanced (18). Consequently, less myocardial inflammation is observed, resulting in less myocardial apoptosis and scar formationreg
s well as enhanced angiogenesis.
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The Dying Stem Cell Hypothesis November 15, 2005:1799–802o investigate whether the beneficial effects can also be
etected with cells other than progenitor cells. The cardiac
unction and outcome should be measured in the different
reatment groups over time. Mechanistically, the use of
nhibitory antibodies against potentially involved anti-
nflammatory mediators, such as the cytokines TGF-beta or
L-10, could help to gain in-depth molecular insight into
he suppression of inflammation by apoptosis.
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